High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
about
P1343
CD133+ anaplastic thyroid cancer cells initiate tumors in immunodeficient mice and are regulated by thyrotropinInvolvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosisNATH, a novel gene overexpressed in papillary thyroid carcinomasUbcH10 overexpression may represent a marker of anaplastic thyroid carcinomasReactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growthGlycerol as a chemical chaperone enhances radiation-induced apoptosis in anaplastic thyroid carcinoma cells.Progress in molecular-based management of differentiated thyroid cancerRAS mutations in thyroid cancerPax-8-PPAR-γ fusion protein in thyroid carcinomaRole of metallothioneins in benign and malignant thyroid lesionsBax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications.Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies.Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer.Thyroid cancer: current molecular perspectives.ABI3 ectopic expression reduces in vitro and in vivo cell growth properties while inducing senescence.Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21.Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71.Prognostic indicators in differentiated thyroid carcinoma.Oncogenes and thyroid cancer.The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas.Scintillation proximity assay for total p53 protein as an alternative to ELISA.MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology.Molecular approaches to thyroid cancer diagnosis.Predictors of thyroid tumor aggressiveness.Old and new insights in the treatment of thyroid carcinoma.Malignancy: Tumor Suppressor Gene Aberrations in Acute Myelogenous Leukemia.Molecular pathogenesis and mechanisms of thyroid cancerP53 mutations in thyroid carcinoma: tidings from an old foe.From amplification to gene in thyroid cancer: a high-resolution mapped bacterial-artificial-chromosome resource for cancer chromosome aberrations guides gene discovery after comparative genome hybridization.p53: the barrier to cancer stem cell formation.Novel approaches in anaplastic thyroid cancer therapymRNA expression in papillary and anaplastic thyroid carcinoma: molecular anatomy of a killing switchTowards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumours.Anaplastic transformation of differentiated thyroid carcinomaMetastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier.Recent advances in molecular diagnosis of thyroid cancer.BCR/ABL genes and leukemic phenotype: from molecular mechanisms to clinical correlations.
P2860
Q21562452-6FF69B04-BC45-4D36-9D0C-0DC465A7C220Q22010480-336D6A46-3197-470E-868F-7AEB6C98C794Q24302202-F760D0E8-6041-4750-9538-FD214F73B258Q24651210-EF7A7C0F-7C29-4F1D-B0FB-B11194DEFFB0Q24651313-A6879E20-08C2-44CA-8280-961C702E84B3Q24796572-7A2728BF-9B80-481F-A7B1-D6D648903CE3Q26999887-A5B67B6F-65B3-4ACD-84F6-EC820843DE10Q27026163-B1283B6D-9F59-45AE-A869-6A87E612FE07Q28244806-3CA1178C-DD6C-48E4-80E1-D8CDA3F21342Q28393061-6A3041DD-B61B-4929-A308-FCC984FAD18BQ33182004-45BA62A1-F0DF-4BA4-A83D-C158D7E991E6Q33385643-AE8177E2-75A5-49E6-9953-01E9FB8BE11FQ33480990-DCAF2766-5D2E-4D21-842C-A067316EB99CQ33691759-1E96F9DF-BB86-40E1-B1A6-109C6A07FDCDQ33707821-3794FC64-B670-4F3A-A706-5EE624E898F4Q33760910-D7511095-29A6-4C70-9ED6-7AD2BFDDCAF3Q33790555-95DFFAEF-E694-4868-B5EE-3295EFF27E44Q33839230-AA3314C5-3C1D-4AEB-A241-ED83F42D343BQ33861404-0F6F651D-4BCF-45F3-B135-6318E6E80FE1Q33914771-F0752D97-3C09-4CF1-87BD-D8CCAE0F6B92Q33930365-15DCE5CB-4328-4BFF-8AF7-942922C914FEQ33931296-4D0E9D98-46E7-4710-A344-99D10F275C9AQ33940788-354FF872-068C-4E2A-9A17-6817D7A0E273Q34077127-0B5C3DED-C789-44A8-9115-138A54B2E380Q34119098-C6C0767F-36AD-4E82-8C5C-F280021E0EB2Q34160828-1A33CB4E-3702-40AF-B004-065FFE0EF2EBQ34184085-0F81C2FA-DE66-4AC5-8466-C52E80EB2C44Q34209934-B92B6A06-A2EA-4982-8979-9A352160E3FDQ34278271-D17753D8-2B03-4D1F-B6E3-3945F07BAC4BQ34329018-1F0FFCBB-BFAD-49CB-9D3E-5BCE08F6414EQ34338919-934FDAA3-8606-4EA3-862D-03C83DCFA956Q34386622-23ABDF43-F071-4090-BD89-64EF67FBD557Q34406072-BF5482A7-C9BB-4466-B9B9-A51AB570B8CDQ34458018-753DBC5A-E24D-44D7-AF20-EEDFED00EB84Q34463393-3118EEBF-5300-4901-98BB-36F8B093F22CQ34592276-E30EA4F6-7A41-4131-8F7F-FE6A33C095FBQ34747425-0D177CBB-03C9-42C3-A524-540541D630C8Q34975148-8EDDE24D-E578-4455-B594-2FED2339449CQ34985320-5C12DF23-B1BA-4F4B-AFAF-47FC53F6B431Q35022548-E885944F-2EC6-4D7D-B5EE-7A6328228E95
P2860
High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
High prevalence of mutations o ...... ated human thyroid carcinomas.
@ast
High prevalence of mutations o ...... ated human thyroid carcinomas.
@en
type
label
High prevalence of mutations o ...... ated human thyroid carcinomas.
@ast
High prevalence of mutations o ...... ated human thyroid carcinomas.
@en
prefLabel
High prevalence of mutations o ...... ated human thyroid carcinomas.
@ast
High prevalence of mutations o ...... ated human thyroid carcinomas.
@en
P2093
P2860
P356
P1476
High prevalence of mutations o ...... ated human thyroid carcinomas.
@en
P2093
P2860
P304
P356
10.1172/JCI116168
P407
P577
1993-01-01T00:00:00Z